Following the launch of two new therapies since last year, Japan has seen fresh moves in drug development for amyotrophic…
HOME > ARCHIVE
ARCHIVE
- Top-4 Generic Makers Report Double-digit Growth in Sales, Profits
June 20, 2011
- Korosho to Permit Telemarketing of OTC Drugs to Residents of Isolated Islands for 2 More Years
June 20, 2011
- Ain Pharmaciez Posts New Record-high Sales
June 20, 2011
- Sawai: Sales, Profits Up Driven by Good Sales to Pharmacies
June 20, 2011
- Takeda Launches Sonias Combination Tablet for Type 2 Diabetes
June 20, 2011
- Sales Down 5.8% for Ethical Drugs in April: Crecon Research & Consulting
June 20, 2011
- Towa: Double-digit Growth in Both Sales, Profits
June 20, 2011
- PAFSC Committee Turns Down Approval of Epogin for Anemia in Cancer Patients
June 20, 2011
- PMDA Should Develop Better Assessment Methods with Industry: Korosho Councilor Hirayama
June 20, 2011
- New Prescription of Actos Suspended in France, Germany due to Bladder Cancer Risk
June 20, 2011
- Development of Anti-obesity Drug Contrave Suspended in US
June 20, 2011
- Chuikyo to Resume Discussions on Next Round of Drug Pricing Reform on June 22
June 20, 2011
- Agensys, Seattle Genetics to Codevelop ADC ASG-22ME: Astellas
June 20, 2011
- PMDA Accelerating Preparations for Membership in PIC/S
June 20, 2011
- DSP, TRANS GENIC, Univ. of Tokyo Sign Joint Research Agreement for AIM
June 20, 2011
- Concern Growing About Gov't Plan to Revise Patients' Drug Copayments
June 20, 2011
- Fujitsu, Univ. of Tokyo to Jointly Develop Technology for Creating LMW Compounds
June 20, 2011
- Fuso Applies for Surgical Hemostatic Product
June 20, 2011
- OncoTherapy Closes Patient Enrollment for PII Trial of OTS102 for Biliary Tract Cancer
June 20, 2011
- CellSeed Applies for Epithelial Cell Sheet for Corneal Regeneration
June 20, 2011
ページ
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…